Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.15.6087

Impact of Prognostic Factors on Survival Rates in Patients with Ovarian Carcinoma  

Arikan, Sevim Kalsen (Obstetrics and Gynecology, Ataturk Training and Research Hospital)
Kasap, Burcu (Obstetrics and Gynecology, Faculty of Medicine, Mugla Sitki Kocman University)
Yetimalar, Hakan (Obstetrics and Gynecology, Ataturk Training and Research Hospital)
Yildiz, Askin (Obstetrics and Gynecology, Ataturk Training and Research Hospital)
Sakarya, Derya Kilic (Obstetrics and Gynecology, Ataturk Training and Research Hospital)
Tatar, Sumeyra (Obstetrics and Gynecology, Faculty of Medicine, Sifa University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.15, 2014 , pp. 6087-6094 More about this Journal
Abstract
Purpose: The aim of the present study was to invesitigate the impact of significant clinico-pathological prognostic factors on survival rates and to identify factors predictive of poor outcome in patients with ovarian carcinoma. Materials and Methods: A retrospective chart review of 74 women with pathologically proven ovarian carcinoma who were treated between January 2006 and April 2011 was performed. Patients were investigated with respect to survival to find the possible effects of age, gravida, parity, menstruel condition, pre-operative Ca-125, treatment period, cytologic washings, presence of ascites, tumor histology, stage and grade, maximal tumor diameter, adjuvan chemotherapy and cytoreductive success. Also 55 ovarian carcinoma patients were investigated with respect to prognostic factors for early 2-year survival. Results: The two-year survival rate was 69% and the 5-year survival rate was 25.5% for the whole study population. Significant factors for 2-year survival were preoperative CA-125 level, malignant cytology and FIGO clinical stage. Significant factors for 5-year survival were age, preoperative CA-125 level, residual tumor, lymph node metastases, histologic type of tumor, malignant cytology and FIGO clinical stage. Logistic regression revealed that independent prognostic factors of 5-year survival were patient age, lymph node metastasis and malignant cytology. Conclusions: We consider quality registries with prospectively collected data to be one important tool in monitoring treatment effects in population-based cancer research.
Keywords
Ovarian cancer; prognostic factors; survival analysis; Turkey;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6.   DOI   ScienceOn
2 Heintz AP, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 161-92.   DOI
3 Hogberg T, Carstensen J, Simonsen E (1993). Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol, 48, 38-49.   DOI   ScienceOn
4 Hoskins WJ, McGuire WP, Brady MF, et al (1994). The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol, 170, 974-9.   DOI   ScienceOn
5 International Federation of Gynecology and Obstetrics (FIGO) (1987). Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol, 56, 263-4.
6 Keettel WC, Pixley E (1958). Diagnostic value of peritoneal washings. Clin Obstet Gynecol, 1, 592-606.   DOI   ScienceOn
7 Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4.   DOI   ScienceOn
8 Li LN, Zhou X, Gu Y, Yan J (2013). Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 4107-13.   과학기술학회마을   DOI   ScienceOn
9 Liu XH, Man YN, Wu XZ (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32.   과학기술학회마을   DOI   ScienceOn
10 Makar AP, Baekelandt M, Trope CG, Kristensen GB (1995). The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol, 56, 175-80.   DOI   ScienceOn
11 Matei MC, Caruntu ID, Negura L, et al (2010). The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev Med Chir Soc Med Nat Iasi, 114, 1135-41.
12 Meyer T, Rustin GJ (2000). Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer, 82, 1535-8.   DOI   ScienceOn
13 Mizuno M, Kikkawa F, Shibata K, et al (2003). Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology, 65, 29-36.
14 Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L (2004). An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a gynecologic oncology group study. Gynecol Oncol, 94, 368-74.   DOI
15 Morton DG, Moore JG, Chang N (1961). The clinical value of peritoneal lavage for cytologic examination. Am J Obstet Gynecol, 81, 1115-25.
16 Panici PB, Maggioni A, Hacker N, et al (2005). Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst, 97, 560-6.   DOI
17 Riman T, Persson I, Nilsson S (1998). Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol, 49, 695-707.   DOI
18 Salzman J, Marinelli RJ, Wang PL, et al (2011). ESRRAC11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol, 9, 1001156.   DOI
19 Riman T, Nilsson S, Persson IR (2004). Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand, 83, 783-95.   DOI
20 Salet-Lizee D, Alsary S (2008). (The place of lumo-aortic and pelvic lymph node dissection in the treatment of ovarian cancer). J Chir (Paris), 145, 45-49.
21 Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25.   DOI   ScienceOn
22 Tang L, Zheng M, Xiong Y, Ding H, Liu FY (2008). Clinical characteristics and prognosis of epithelial ovarian cancer in young women. Ai Zheng, 27, 951-5.
23 Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003). Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol, 101, 885-91.   DOI   ScienceOn
24 Vergote I, De Brabanter J, Fyles A, et al (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, 357, 176-182.   DOI   ScienceOn
25 Wan WN, Zhang YX, Wang XM, et al (2014). ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. Asian Pac J Cancer Prev, 15, 2777-83   과학기술학회마을   DOI
26 Zuna RE, Behrens A (1996). Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst, 88, 980-7.   DOI
27 Chan JK, Loizzi V, Lin YG, et al (2003). Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol, 102, 156-61.   DOI
28 Abe A, Furumoto H, Irahara M, et al (2010). The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer. J Obstet Gynaecol Res, 36, 1023-30.   DOI
29 Bosze P, Bast RC, Berchuck A, et al (2000). Conseusus statements on prognostic factors in epithelial ovarian carcinoma. report of the consensus meeting organized by the european society of gynaecological oncology, ESGO. Eur J Gynaecol Oncol, 21, 513-26.
30 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59.   DOI   ScienceOn
31 Chan JK, Cheung MK, Husain A, et al (2006). Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol, 108, 521-8.   DOI
32 Chan JK, Loizzi V, Lin YG, et al (2006). Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer, 95, 1314-20.   DOI
33 Chi DS, Eisenhauer EL, Lang J, et al (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol, 103, 559-64.   DOI   ScienceOn
34 Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF (2001). A prognostic model for ovarian cancer. Br J Cancer, 85, 944-52.   DOI   ScienceOn
35 Cooper BC, Sood AK, Davis CS, et al (2002). Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol, 100, 59-64.   DOI   ScienceOn
36 Duffy MJ, Bonfrer JM, Kulpa J, et al (2005). CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer, 15, 679-91.   DOI
37 Coussy F, Chereau E, Darai E, et al (2011). Interest of CA 125 level in management of ovarian cancer. Gynecol Obstet Fertil, 39, 296-301.   DOI
38 Creasman WT, Rutledge F (1971). The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol, 110, 773-81.
39 Du Bois A, Rochon J, Lamparter C, Pfisterer J; AGO Organkommission OVAR PFisterer (2005). Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer, 15, 183-91.   DOI
40 Eisenkop SM, Spirtos NM, Friedman RL, et al (2003). Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol, 90, 390-6.   DOI   ScienceOn
41 Gaemmaghami F, Yousefi Z, Gilani M, Mosavi A, Shariat M (2011). Role of appropriate surgery in survival of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev, 12, 253-7.
42 Gerestein CG, Eijkemans MJ, de Jong D, et al (2009). The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG, 116, 372-80.   DOI
43 Gertig D, Hunter D (2002). Ovarian cancer. In: Adami H, Hunter D, Trichopoulos D, eds. Textbook of cancer epidemiology. Oxford: Oxford University Press, 378-99.
44 Griffiths CT (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr, 42, 101-4.
45 Du Bois A, Reuss A, Pujade-Lauraine E, et al (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115, 1234-44.   DOI   ScienceOn
46 Braem MG, Onland-Moret NC, van den Brandt PA, et al (2010). Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol, 172, 1181-9.   DOI